Latest & greatest articles for carisoprodol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on carisoprodol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on carisoprodol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for carisoprodol

1. Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose. (PubMed)

Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose. Carisoprodol, a centrally acting muscle relaxant with a high abuse potential, has barbiturate-like properties at the GABA-A receptor, leading to central nervous system depression and desired effects. Its tolerance and dependence has been previously demonstrated in an animal model, and withdrawal has been described in several recent case reports. Many cases can be effectively managed with a short course (...) of benzodiazepines or antipsychotic agents. However, abrupt cessation in a patient with a history of long-term and high-dose carisoprodol abuse may result in symptoms that are more difficult for providers to treat.We present a case of a 34-year-old man with a long history of carisoprodol abuse who was found unresponsive after having ingested 7.5 grams of carisoprodol. He was intubated and admitted to the intensive care unit. He was given propofol, dexmedetomidine, fentanyl, ketamine, lorazepam, midazolam

2016 Journal of Emergency Medicine

2. Randomized, double-blind trial of carisoprodol 250 mg compared with placebo and carisoprodol 350 mg for the treatment of low back spasm. (PubMed)

Randomized, double-blind trial of carisoprodol 250 mg compared with placebo and carisoprodol 350 mg for the treatment of low back spasm. Carisoprodol, a centrally active skeletal muscle relaxant, is widely used for the treatment of acute, painful musculoskeletal disorders. When administered at a dose of 350 mg four times daily, carisoprodol demonstrated significant clinical benefit in its early clinical development trials; however, some unfavorable side effects, such as drowsiness and dizziness (...) , were reported. Recently, research was conducted to determine if a lower dose of carisoprodol would retain efficacy but improve tolerability compared to the higher 350-mg dose.The purpose of this multicenter study was to compare the efficacy and safety of carisoprodol 250-mg tablets four times daily to 350-mg tablets four times daily and to placebo in patients with acute, painful musculoskeletal spasm of the lower back.In this 1-week double-blind, placebo-controlled, parallel-group multicenter trial

2010 Current medical research and opinion Controlled trial quality: predicted high

3. Carisoprodol

Carisoprodol Top results for carisoprodol - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for carisoprodol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

4. Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers. (PubMed)

Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers. Some chronic pain patients on long-term opioid therapy also take centrally active skeletal muscle relaxants. One of those muscle relaxants is carisoprodol, a drug that is abused and capable of producing impairment. It would be of relevance to characterize the effects of an opioid and carisoprodol when taken together to determine if abuse liability-related measures and psychomotor impairment (...) are increased compared to when the drugs are taken alone.As part of a larger crossover, randomized, double-blind study, we examined the subjective and psychomotor responses of 15 healthy volunteers to four experimental conditions: placebo, 350 mg carisoprodol, 10mg oxycodone, and 350 mg carisoprodol followed 60 min later by 10mg oxycodone (intended to test the interaction of the two drugs when they were producing their maximal effects).Preliminary data analyses indicated that some of carisoprodol's effects

Full Text available with Trip Pro

2012 Drug and alcohol dependence Controlled trial quality: uncertain

5. A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol

A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01421433 Recruitment Status : Unknown Verified

2011 Clinical Trials

6. Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers. (PubMed)

Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers. Carisoprodol is a centrally acting drug used to relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. There is evidence from different sources that this oral muscle relaxant is abused and that it is associated with impairment leading to arrests for "driving under the influence" as well as increased risk of automobile accidents. Its subjective and psychomotor effects (...) in healthy volunteers at therapeutic and supratherapeutic doses have not been well-characterized, and form the basis of this report. Fifteen healthy volunteers (8 males, 7 females) were administered 0, 350, and 700 mg of carisoprodol in separate sessions and for 6h afterwards they completed a battery of tests at fixed time intervals so as to assess the subjective and psychomotor effects of the drug. The supratherapeutic dose, 700 mg, increased visual analog scale ratings of terms that were more

Full Text available with Trip Pro

2011 Pharmacology, biochemistry, and behavior Controlled trial quality: uncertain

7. Bioavailability of oral carisoprodol 250 and 350 mg and metabolism to meprobamate: A single-dose crossover study. (PubMed)

Bioavailability of oral carisoprodol 250 and 350 mg and metabolism to meprobamate: A single-dose crossover study. Carisoprodol is a skeletal muscle relaxant indicated for use in the treatment of acute, painful musculoskeletal conditions. Two randomized, controlled clinical trials have reported that carisoprodol 250 mg QID was equally effective as and better tolerated than carisoprodol 350 mg QID.The primary objective of the current study was to determine the relative bioavailability (...) of carisoprodol and its metabolite, meprobamate, with singledose administration of 250- and 350-mg tablets. A secondary objective of the study was to determine whether lowering the carisoprodol dose would decrease plasma meprobamate concentrations.This single-dose, randomized, open-label, crossover study enrolled healthy volunteers. Each dose was administered with water in the morning; after a 7-day washout, subjects received the alternate dose. Blood samples were drawn at prespecified times over a 48-hour

Full Text available with Trip Pro

2010 Current therapeutic research, clinical and experimental Controlled trial quality: uncertain

8. A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00671502 Recruitment Status : Completed First Posted : May 5, 2008 Results First

2008 Clinical Trials

9. Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. (PubMed)

Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. The effects of carisoprodol and a placebo were compared in a sample of 60 patients with the clinical diagnosis of myofascial pain-dysfunction syndrome using double-blind design. Carisoprodol failed to show a significantly greater effect than the placebo. The side effects were about the same with both agents.

1975 Journal of oral surgery (American Dental Association : 1965)

10. Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.

Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study (...) record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. (Delfos

2018 Clinical Trials

11. Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. (PubMed)

Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. A double-blind study was carried out to determine the effectiveness of a muscle relaxant, carisoprodol, in the treatment of the low back syndrome, and to test whether this drug would produce any greater effect than an active sedative control. Forty-eight Mexican migrant farm laborers with acute lumbar strain and spasm were given either carisoprodol 350 mg, butabarbital 15 mg, or placebo, four times (...) daily for four days, and then were rated on pertinent symptoms, the degree of limitation of motion (by an objective finger-to-floor test), and overall improvement. In the 43 patients who could be statistically analyzed, carisoprodol was shown to be significantly more effective than butabarbital or placebo in producing improvement of all factors rated. This result suggests that the effects of carisoprodol are not due solely to sedative action, but are also related to its muscle relaxant activity.

Full Text available with Trip Pro

1972 California medicine

12. Carisoprodol abuse in Texas, 1998–2003 (PubMed)

Carisoprodol abuse in Texas, 1998–2003 Texas poison centers identified carisoprodol as a skeletal muscle relaxant that is subject to abuse, and this investigation explores the abuse reported by Texas poison centers.This study used data from six Texas poison centers to describe the epidemiology of carisoprodol abuse and drug identification (ID) calls from 1998 to 2003.Drug ID and abuse calls were 217% higher in 2003 than in 1998. Although eastern and central Texas contains 43% of the state's (...) population, this region reported 77% of all drug ID calls and 64% of abuse calls. For male patients, 51% of the calls were abuse calls and 37% were other human carisoprodol exposure calls. Patients from 13 to 19 years of age accounted for 17% of abuse calls and 9% of other human exposure calls. Among those human exposure calls with a known medical outcome, a higher percentage of abuse calls involved minor effects while a greater proportion of other human exposure calls involved outcomes that ranged from

Full Text available with Trip Pro

2006 Journal of Medical Toxicology

13. An experimental investigation of the change effected by the ingestion of carisoprodol, aspirin, codeine, and a placebo upon the threshold for deep pain induced by ultrasonic stimulation. (PubMed)

An experimental investigation of the change effected by the ingestion of carisoprodol, aspirin, codeine, and a placebo upon the threshold for deep pain induced by ultrasonic stimulation. 14402682 1998 11 01 2018 12 01 0077-8923 86 1960 Mar 30 Annals of the New York Academy of Sciences Ann. N. Y. Acad. Sci. An experimental investigation of the change effected by the ingestion of carisoprodol, aspirin, codeine, and a placebo upon the threshold for deep pain induced by ultrasonic stimulation. 147 (...) -61 HOLLIDAY A R AR DILLE J M JM eng Journal Article United States Ann N Y Acad Sci 7506858 0077-8923 0 Muscle Relaxants, Central 21925K482H Carisoprodol Q830PW7520 Codeine R16CO5Y76E Aspirin OM Analgesia Anesthesia Anesthesia and Analgesia Aspirin pharmacology Carisoprodol Codeine Humans Muscle Relaxants, Central pharmacology Pain Pain Management Ultrasonic Therapy ACETYLSALICYLIC ACID/pharmacology CODEINE/anesthesia and analgesia MUSCLE RELAXANTS/pharmacology 1960 3 30 1960 3 30 0 1 1960 3 30 0

1998 Annals of the New York Academy of Sciences Controlled trial quality: uncertain

14. CARISOPRODOL IN CEREBRAL PALSY: A CONTROLLED TRIAL. (PubMed)

CARISOPRODOL IN CEREBRAL PALSY: A CONTROLLED TRIAL. 14090619 1996 12 01 2018 12 01 0012-1622 5 1963 Dec Developmental medicine and child neurology Dev Med Child Neurol CARISOPRODOL IN CEREBRAL PALSY: A CONTROLLED TRIAL. 603-8 GOOCH J M JM eng Journal Article England Dev Med Child Neurol 0006761 0012-1622 0 Placebos 21925K482H Carisoprodol GWH6IJ239E Amobarbital OM Amobarbital Carisoprodol Cerebral Palsy Child Humans Infant, Newborn Placebos AMOBARBITAL CARISOPRODOL CEREBRAL PALSY CHILD INFANT

1996 Developmental Medicine and Child Neurology Controlled trial quality: predicted high

15. Mass spectrometric analysis of carisoprodol and meprobamate in rat brain microdialysates (PubMed)

Mass spectrometric analysis of carisoprodol and meprobamate in rat brain microdialysates We report the evaluation of several mass spectrometry-based methods for the determination of carisoprodol and meprobamate in samples obtained from the rat brain by in vivo intracranial microdialyis. Among the techniques that aspire to perform analyses without chromatographic separation and thereby increase throughput, chip-based nanoelectrospray ionization and the use of an atmospheric pressure solids (...) analysis probe fell short of requirements because of insufficient detection sensitivity and hard ionization, respectively. Although direct analysis in real time provided the required soft ionization, shortcomings of a tandem mass spectrometry-based assay also included inadequate detection sensitivity and, in addition, poor quantitative reproducibility. Therefore, liquid chromatography coupled with atmospheric pressure chemical ionization tandem mass spectrometry was developed to determine carisoprodol

Full Text available with Trip Pro

2016 Journal of mass spectrometry : JMS

16. A Single Amino Acid Residue at Transmembrane Domain 4 of the α Subunit Influences Carisoprodol Direct Gating Efficacy at GABAA Receptors (PubMed)

A Single Amino Acid Residue at Transmembrane Domain 4 of the α Subunit Influences Carisoprodol Direct Gating Efficacy at GABAA Receptors The muscle relaxant carisoprodol has recently been controlled at the federal level as a Schedule IV drug due to its high abuse potential and consequences of misuse, such as withdrawal syndrome, delusions, seizures, and even death. Recent work has shown that carisoprodol can directly gate and allosterically modulate the type A GABA (GABAA) receptor (...) . These actions are subunit-dependent; compared with other GABAA receptors, carisoprodol has nominal direct gating effects in α3β2γ2 receptors. Here, using site-directed mutagenesis and whole-cell patch-clamp electrophysiology in transiently transfected human embryonic kidney 293 cells, we examined the role of GABAA receptor α subunit transmembrane domain 4 (TM4) amino acids in direct gating and allosteric modulatory actions of carisoprodol. Mutation of α3 valine at position 440 to leucine (present

Full Text available with Trip Pro

2017 The Journal of pharmacology and experimental therapeutics

17. Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00671879 Recruitment Status : Completed First Posted : May 5, 2008 Results First

2008 Clinical Trials

18. Carisoprodol withdrawal syndrome. (PubMed)

Carisoprodol withdrawal syndrome. A 43-year-old man with chronic back and shoulder pain was treated with hydrocodone. He began taking excessive amounts of the drug, so his physicians stopped prescribing it. The patient then obtained the muscle relaxant carisoprodol on his own from several sources. He was consuming up to 30 or more tablets/day (> or =10,500 mg/day) for several weeks, then abruptly stopped taking the drug. Within 48 hours he developed anxiety, tremors, muscle twitching, insomnia (...) , auditory and visual hallucinations, and bizarre behavior. The symptoms intensified and peaked on the fourth day after carisoprodol cessation. The patient required brief treatment with olanzapine and tapering dosages of lorazepam while the symptoms gradually resolved. To our knowledge, this is the first documented case of a withdrawal syndrome with carisoprodol. The symptoms most likely resulted because of accumulation of meprobamate, the active metabolite of carisoprodol in humans. Clinicians

2004 Pharmacotherapy

19. Is the frequency of carisoprodol withdrawal syndrome increasing? (PubMed)

Is the frequency of carisoprodol withdrawal syndrome increasing? Carisoprodol is a commonly used centrally acting muscle relaxant. A number of case reports have suggested that the drug may have abuse potential, presumably because it is metabolized to the anxiolytic drug, meprobamate, which is a controlled substance at the federal level. Two recent case reports described symptoms of withdrawal after the cessation of carisoprodol. We present two additional cases that support the concept (...) of a withdrawal syndrome with this drug. Symptoms of carisoprodol withdrawal include anxiety, tremulousness, insomnia, jitteriness, muscle twitching, and hallucinations. These symptoms are most likely caused by withdrawal from the meprobamate that accumulates after large amounts of carisoprodol are ingested. Although carisoprodol is not a controlled substance at the federal level, clinicians should be aware of its significant potential for abuse.

2007 Pharmacotherapy

20. Double-blind trial of carisoprodol. (PubMed)

Double-blind trial of carisoprodol. 14001807 1998 11 01 2018 12 01 0012-1622 4 1962 Oct Developmental medicine and child neurology Dev Med Child Neurol Double-blind trial of carisoprodol. 499-506 WOODS G E GE eng Journal Article England Dev Med Child Neurol 0006761 0012-1622 21925K482H Carisoprodol OM Athetosis Carisoprodol Cerebral Palsy Double-Blind Method Humans ATHETOSIS CARISOPRODOL CEREBRAL PALSY 1962 10 1 1962 10 1 0 1 1962 10 1 0 0 ppublish 14001807

1998 Developmental Medicine and Child Neurology Controlled trial quality: predicted high